Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL002 long-term extension study in Alzheimer's disease
NL-OMON53422Phase 2Not yet recruiting
- Sponsor
- Alector
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AL002 in Alzheimer's disease (AD) (3 arms), sponsored by Alector. Primary endpoints: Incidence of adverse events, Clinical safety assessments and 5 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
AL002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON53422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53422.